The use of serum ceramide levels as a biological marker has been established for other neurological (32, 33) and non-neurological diseases such as chronic kidney disease and Alzheimer's disease (34, 35), but not in CLN3 disease. Here, CLN3 is linked to early-onset autosomal dominant Alzheimer disease.